Abstract 253P
Background
Nonepithelial ovarian cancers constitute about 10 % of all ovarian cancers. They are divided into sex-cord stromal tumours (SCST) and germ cell tumours (GCT). The Aim is to report the experience at National Centre for Cancer Care and Research (NCCCR) in Qatar.
Methods
This is a retrospective study reviewing records of all patients who presented with a histopathologically diagnosed ovarian SCST and GCT at NCCCR between January 2010 and December 2016. Clinical data including age, stage at diagnosis, histopathology, treatment modalities, disease recurrence and status at last follow up was extracted.
Results
A Total of 25 women with Non Epithelial Ovarian Tumours were identified. 13 women were diagnosed with Ovarian SCST. 12 had granulosa cell tumour , 1 with steroid cell tumour and none of them had Sertoli-Leydig cell tumor. Median age at presentation was 43 years (Range 16-58). 12 patients (92 %) had stage I and 1 patient (8 %) had Stage III. 9 patients had TAH + BSO . 4 patients had conservative surgery without hysterectomy. 2 patients received Adjuvant chemotherapy .4 patients had recurrence. The 5 years Overall Survival (OS) was 100% and the 5 years Event Free Survival (EFS) was 69% with P value of 0.02.
GCT was diagnosed in 12 women. The median age at presentation was 24 years (Range 16 – 44). 7 patients (59 %) had teratoma, 4 patients (33 %) had Dysgerminoma and 1 patient had Yolk sac tumour (8 %). 9 patients ( 75 % ) had Stage 1, 2 patients had Stage 2 ( 17 % ) and 1 patient ( 8 % ) had Stage 4 disease .6 patients ( 50 % ) underwent U/L Oopherectomy .5 patients ( 42 % ) underwent U/L salpingoOopherctomy and Chemotherapy( BEP ) .1 pt. ( 8 % ) with Stage IV disease received only chemotherapy. There was 1 recurrence in the Retroperitoneal LNs in patient with Stage 2 disease. 5 years OS was 100 % and 5 years EFS was 83 % with P value of 0.14.
Conclusions
Survival in our study of SCST was excellent with all patients alive and disease free at last follow up. We recommend Complete Surgery (TAH + BSO) particularly if high grade, Stage 1C and above or completed child bearing to minimize recurrence.
GCTs have very good prognosis in all stages and even in recurrence. Fertility Sparing Surgery is appropriate for all patients with Stage 1 and most of patients with Stage 2 disease who desire fertility preservation.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
393P - Clinical characteristics and prognosis of patients with pulmonary mucoepidermoid carcinoma: A SEER-based analysis
Presenter: Lingxiao Qiu
Session: e-Poster Display Session
394P - Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients: A multicenter, single arm, phase II clinical trial
Presenter: Zhen He
Session: e-Poster Display Session
395P - Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
396P - Efficacy and safety of S-1 in elderly patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A subgroup analysis of the EAST-LC
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
397P - A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients
Presenter: Ching-Liang Ho
Session: e-Poster Display Session
398P - Real-world mechanism of crizotinib-resistance in MET exon 14 skipping mutations non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Dong Wang
Session: e-Poster Display Session
399P - Real-world insights into patients (pts) with advanced NSCLC and MET alterations
Presenter: Marisa Bittoni
Session: e-Poster Display Session
400P - Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study
Presenter: Maximilian J. Hochmair
Session: e-Poster Display Session
401P - A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
Presenter: Satoshi Igawa
Session: e-Poster Display Session
402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Presenter: Zhehai Wang
Session: e-Poster Display Session